Covered recipient · General Payments record
GUILLERMO VALENZUELA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$185,529.14
288 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $109,275.45 | 37 |
| Consulting Fee | $42,243.00 | 10 |
| Travel and Lodging | $27,898.66 | 78 |
| Food and Beverage | $6,112.03 | 163 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $44,184.57 | 69 |
| GENZYME CORPORATION | $39,628.63 | 33 |
| GlaxoSmithKline, LLC. | $22,390.37 | 21 |
| Janssen Biotech, Inc. | $16,011.48 | 18 |
| Amgen Inc. | $13,330.77 | 40 |
| ABBVIE INC. | $11,041.51 | 26 |
| Novartis Pharmaceuticals Corporation | $10,379.43 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,781.32 | 11 |
| Mylan Inc. | $6,085.79 | 2 |
| IDORSIA PHARMACEUTICALS US INC | $5,000.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $3,436.13 | 9 |
| SOBI, INC | $2,788.05 | 3 |
| E.R. Squibb & Sons, L.L.C. | $1,693.56 | 8 |
| Mallinckrodt Hospital Products Inc. | $125.65 | 4 |
| ANI Pharmaceuticals, Inc. | $120.33 | 4 |
| Radius Health, Inc. | $117.22 | 4 |
| CSL Behring | $77.64 | 3 |
| Janssen Research & Development, LLC | $73.09 | 2 |
| Alvogen Inc | $62.41 | 3 |
| Sandoz Inc. | $53.06 | 3 |
| PFIZER INC. | $31.28 | 2 |
| Aurinia Pharma U.S., Inc. | $25.70 | 1 |
| Solta Medical, a division of Bausch Health US, LLC | $24.61 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.81 | 1 |
| Grifols USA, LLC | $23.40 | 1 |
| Genentech USA, Inc. | $19.33 | 1 |
Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GUILLERMO VALENZUELA
NPI 1245252402 · CMS profile ID 101277
PLANTATION, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
288 matching records · $185,529.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 288.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Solta Medical, a division of Bausch Health US, LLC | $24.61 | 08/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206128511 | CMS |
| Alvogen Inc | $23.11 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1209953036 | CMS |
| GlaxoSmithKline, LLC. | $650.00 | 08/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190400774 | CMS |
| GlaxoSmithKline, LLC. | $650.00 | 08/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191720333 | CMS |
| Mallinckrodt Hospital Products Inc. | $21.56 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212005293 | CMS |
| SOBI, INC | $114.92 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240239421 | CMS |
| GlaxoSmithKline, LLC. | $25.74 | 08/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190895986 | CMS |
| Amgen Inc. | $25.40 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228354944 | CMS |
| GENZYME CORPORATION | $10.98 | 08/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300138 | CMS |
| GENZYME CORPORATION | $31.16 | 08/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300140 | CMS |
| GENZYME CORPORATION | $7,632.00 | 08/10/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300314 | CMS |
| GENZYME CORPORATION | $389.83 | 08/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300316 | CMS |
| GENZYME CORPORATION | $680.17 | 08/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300318 | CMS |
| GENZYME CORPORATION | $249.88 | 08/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300320 | CMS |
| GENZYME CORPORATION | $142.28 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300258 | CMS |
| ABBVIE INC. | $13.25 | 08/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611742 | CMS |
| GENZYME CORPORATION | $6.11 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300302 | CMS |
| Amgen Inc. | $4.60 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227095639 | CMS |
| Amgen Inc. | $6.04 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227095643 | CMS |
| ANI Pharmaceuticals, Inc. | $24.75 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248613281 | CMS |
| UCB, Inc. | $6,000.00 | 07/31/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353120 | CMS |
| ABBVIE INC. | $33.91 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611735 | CMS |
| ABBVIE INC. | $41.42 | 07/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611739 | CMS |
| GlaxoSmithKline, LLC. | $30.46 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191762464 | CMS |
| Novartis Pharmaceuticals Corporation | $24.98 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200384814 | CMS |
| ABBVIE INC. | $229.82 | 07/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611731 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.87 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184918534 | CMS |
| Radius Health, Inc. | $31.36 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249509994 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.19 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214804630 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 07/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190519390 | CMS |
| Janssen Biotech, Inc. | $5,075.00 | 07/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175222651 | CMS |
| Janssen Biotech, Inc. | $5.49 | 07/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175223235 | CMS |
| Janssen Biotech, Inc. | $42.75 | 07/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175223921 | CMS |
| UCB, Inc. | $18.11 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353118 | CMS |
| Amgen Inc. | $6.81 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227095647 | CMS |
| AstraZeneca Pharmaceuticals LP | $5.34 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215340722 | CMS |
| UCB, Inc. | $125.00 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353114 | CMS |
| UCB, Inc. | $1,317.93 | 07/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353116 | CMS |
| GENZYME CORPORATION | $23.12 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300254 | CMS |
| ABBVIE INC. | $17.77 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611727 | CMS |
| UCB, Inc. | $15.00 | 07/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353112 | CMS |
| ABBVIE INC. | $175.00 | 07/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611716 | CMS |
| ABBVIE INC. | $775.00 | 07/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611719 | CMS |
| ABBVIE INC. | $3,600.00 | 07/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611723 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $5,000.00 | 07/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243416780 | CMS |
| Janssen Biotech, Inc. | $1,450.00 | 06/28/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175223254 | CMS |
| UCB, Inc. | $1,775.00 | 06/26/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224353110 | CMS |
| ABBVIE INC. | $570.40 | 06/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611707 | CMS |
| ABBVIE INC. | $724.72 | 06/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204611712 | CMS |
| GENZYME CORPORATION | $148.12 | 06/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233300272 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,099,441.21 | 158 |
| PY2024 | Recipient | $6,385.02 | 1 |
| PY2024 | Principal investigator | $2,370,149.15 | 81 |
| PY2023 | Recipient | $2,369.50 | 1 |
| PY2023 | Principal investigator | $1,705,553.77 | 58 |
| PY2022 | Recipient | $1,219.06 | 3 |
| PY2022 | Principal investigator | $2,396,921.97 | 53 |
| PY2021 | Recipient | $1,791.00 | 2 |
| PY2021 | Principal investigator | $1,602,769.13 | 98 |
| PY2020 | Recipient | $14,554.37 | 6 |
| PY2020 | Principal investigator | $1,165,555.50 | 146 |
| PY2019 | Recipient | $75,629.31 | 3 |
| PY2019 | Principal investigator | $1,346,131.53 | 128 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
158 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $3,913.22 | 12/25/2025 | Non-covered Recipient Entity IRIS Research and Development LLC | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228817022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,028.00 | 12/22/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411698 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,698.59 | 12/19/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223290026 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,272.70 | 12/17/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289902 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,405.52 | 12/16/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) | No dispute reported | 06/30/2026 | 1190309362 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/15/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,970.00 | 12/15/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411628 |
| Principal investigator 1 | ABBVIE INC. | $8,940.00 | 12/04/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202526894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 12/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 12/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667170 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.00 | 12/01/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190301437 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,040.99 | 12/01/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289138 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,090.70 | 11/13/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220792001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,948.00 | 11/10/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411729 |
| Principal investigator 1 | ABBVIE INC. | $68.75 | 11/04/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202520695 |
| Principal investigator 1 | ABBVIE INC. | $18,710.00 | 11/04/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 11/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 11/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,875.00 | 10/31/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411563 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,625.00 | 10/27/2025 | Non-covered Recipient Entity Iris Research And Development LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226128107 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,500.00 | 10/20/2025 | Non-covered Recipient Entity Iris Research And Development LLC | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128103 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,562.72 | 10/17/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223287139 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,283.14 | 10/15/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223287009 |
| Principal investigator 1 | ABBVIE INC. | $1,908.58 | 10/09/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202515593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,344.40 | 10/06/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,866.00 | 10/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,200.00 | 10/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 10/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 10/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667158 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,575.99 | 10/01/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190301447 |
| Principal investigator 1 | Amgen Inc. | $39,197.88 | 09/26/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246642995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 09/24/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.02 | 09/24/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.16 | 09/24/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.28 | 09/24/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667152 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 09/22/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411528 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,542.40 | 09/17/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285590 |
| Principal investigator 1 | ARGENX US, INC. | $3,500.00 | 09/12/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis | No dispute reported | 06/30/2026 | 1237151245 |
| Principal investigator 1 | ARGENX US, INC. | $26,212.00 | 09/12/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis | No dispute reported | 06/30/2026 | 1237151248 |
| Principal investigator 1 | Amgen Inc. | $53,042.10 | 09/10/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246642985 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,000.00 | 09/03/2025 | Non-covered Recipient Entity Iris Research And Development LLC | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 09/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 09/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667134 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,038.00 | 09/01/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,389.00 | 08/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411574 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,750.00 | 08/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411621 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,928.20 | 08/22/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284545 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,568.00 | 08/21/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | No dispute reported | 06/30/2026 | 1190301445 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,687.50 | 08/18/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791997 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,016.03 | 08/15/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284303 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,136.00 | 08/11/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411605 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $54,207.50 | 08/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT | A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185549101 |
| Principal investigator 1 | ABBVIE INC. | $2,272.33 | 08/05/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202501960 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 08/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 08/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667128 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,595.80 | 08/01/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283577 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,132.40 | 08/01/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283579 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,200.00 | 08/01/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,961.00 | 07/31/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411558 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,200.00 | 07/31/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411718 |
| Principal investigator 1 | UCB SA | $50,256.00 | 07/30/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246658650 |
| Principal investigator 1 | Amgen Inc. | $1,614.43 | 07/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246642992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 07/28/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 07/28/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.04 | 07/28/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.32 | 07/28/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.56 | 07/28/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667144 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,000.00 | 07/28/2025 | Non-covered Recipient Entity Iris Research And Development LLC | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128093 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,103.10 | 07/23/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,334.14 | 07/18/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282798 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,296.00 | 07/11/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411568 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,159.00 | 07/07/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,750.00 | 07/07/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,872.00 | 07/04/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175411669 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,000.00 | 07/02/2025 | Non-covered Recipient Entity Iris Research And Development LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226128083 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,500.00 | 07/02/2025 | Non-covered Recipient Entity Iris Research And Development LLC | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128088 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,555.45 | 07/02/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282154 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,000.00 | 07/02/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 07/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 07/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667122 |
| Principal investigator 1 | PFIZER INC. | $13,660.00 | 06/28/2025 | Non-covered Recipient Entity IRIS Research and Development LLC | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228851856 |
| Principal investigator 1 | Amgen Inc. | $18,940.00 | 06/04/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246643012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,422.00 | 06/02/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,657.00 | 06/02/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 06/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667114 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 06/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667116 |
| Principal investigator 1 | Mallinckrodt Hospital Products Inc. | $80,000.00 | 05/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | CLINICAL IMPACT OF ACTHAR IN THE PSORIATIC ARTHRITIS PATIENT | No dispute reported | 06/30/2026 | 1212110464 |
| Principal investigator 1 | Amgen Inc. | $609.13 | 05/27/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS | A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy | No dispute reported | 06/30/2026 | 1246642790 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,897.00 | 05/26/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175411704 |
| Principal investigator 1 | Eli Lilly and Company | $7,475.00 | 05/23/2025 | Non-covered Recipient Entity IRIS RSRCH AND DEVELOPMENT | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187883140 |
| Principal investigator 1 | Amgen Inc. | $42,134.36 | 05/21/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246643007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,800.00 | 05/09/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,140.00 | 05/08/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411633 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,687.50 | 05/07/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791993 |
| Principal investigator 1 | ABBVIE INC. | $2,529.83 | 05/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202481645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 05/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 05/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667110 |
| Principal investigator 1 | Amgen Inc. | $56,464.06 | 04/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | P4 Uncontrolled Gout FORWARD II | No dispute reported | 06/30/2026 | 1246643003 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 04/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,494.00 | 04/11/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,200.00 | 04/07/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411600 |
| Principal investigator 1 | ABBVIE INC. | $123.95 | 04/03/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202468972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 04/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667102 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 04/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,614.00 | 03/31/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411693 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,000.00 | 03/14/2025 | Non-covered Recipient Entity IRIS RESEARCH DEVELOPMENT LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223276737 |
| Principal investigator 1 | UCB SA | $888.26 | 03/12/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246658414 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,880.60 | 03/10/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,756.00 | 03/10/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175411536 |
| Principal investigator 1 | ABBVIE INC. | $383.75 | 03/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202458176 |
| Principal investigator 1 | UCB SA | $181.07 | 03/06/2025 | Non-covered Recipient Entity INTERGRAL RHEUMATOLOGY & IMMUNOLOGY SPECIALIST | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246657650 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,200.00 | 03/03/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411610 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,917.00 | 03/03/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 03/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667096 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 03/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,719.00 | 02/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411640 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $725.00 | 02/25/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment | No dispute reported | 06/30/2026 | 1190309686 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,142.00 | 02/14/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175411688 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $470.67 | 02/10/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | No dispute reported | 06/30/2026 | 1190301441 |
| Principal investigator 1 | ABBVIE INC. | $1,764.63 | 02/05/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202444455 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,750.00 | 02/05/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190309692 |
| Principal investigator 1 | UCB SA | $22,976.00 | 02/05/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246659535 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,578.00 | 02/03/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175411710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 02/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667088 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 02/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667090 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667092 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,880.50 | 02/01/2025 | Non-covered Recipient Entity Iris Research and Development LLC | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220791989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,296.00 | 01/31/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175411541 |
| Principal investigator 1 | Amgen Inc. | $6,247.31 | 01/30/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS | A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1246642794 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58,166.00 | 01/28/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | No dispute reported | 06/30/2026 | 1190309690 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,227.00 | 01/27/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175411682 |
| Principal investigator 1 | UCB SA | $26,993.00 | 01/27/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246657352 |
| Principal investigator 1 | Eli Lilly and Company | $10,204.00 | 01/21/2025 | Non-covered Recipient Entity IRIS RSRCH AND DEVELOPMENT | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187883138 |
| Principal investigator 1 | Amgen Inc. | $664,132.26 | 01/17/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246643000 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $45.32 | 01/15/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | No dispute reported | 06/30/2026 | 1190301435 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43.50 | 01/15/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190301443 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,295.90 | 01/14/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A randomized double blind placebo controlled multicenter phase 2 dose ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1190309688 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $91,350.00 | 01/13/2025 | Non-covered Recipient Entity Iris Research And Development LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226128071 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,100.00 | 01/13/2025 | Non-covered Recipient Entity Iris Research And Development LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226128075 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,200.00 | 01/13/2025 | Non-covered Recipient Entity Iris Research And Development LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226128079 |
| Principal investigator 1 | Eli Lilly and Company | $817.77 | 01/09/2025 | Non-covered Recipient Entity IRIS RSRCH AND DEVELOPMENT | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187885188 |
| Principal investigator 1 | Amgen Inc. | $91,785.15 | 01/06/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246642989 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $49,373.54 | 01/03/2025 | Non-covered Recipient Entity IRIS RESEARCH AND DEVELOPMENT | Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | No dispute reported | 06/30/2026 | 1185549103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.58 | 01/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.19 | 01/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Integral Rheumatology And Immunology Specialists-Plantation FL | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220667086 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $457.60 | 01/01/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190301439 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,583.05 | 01/01/2025 | Non-covered Recipient Entity INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS . | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190301449 |